• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Vaccine . Unveiling the multi-characteristic potential of hyper-productive suspension MDCK cells for advanced influenza A virus propagation

tetano

Editor, Senior Moderator
Vaccine


. 2025 Feb 21:52:126900.
doi: 10.1016/j.vaccine.2025.126900. Online ahead of print. Unveiling the multi-characteristic potential of hyper-productive suspension MDCK cells for advanced influenza A virus propagation

Qian Ye[SUP] 1 [/SUP], Zhiying Xiao[SUP] 1 [/SUP], Chunli Bai[SUP] 2 [/SUP], Hong Yao[SUP] 2 [/SUP], Liang Zhao[SUP] 3 [/SUP], Wen-Song Tan[SUP] 4 [/SUP]



Affiliations
Abstract

The global population faces persistent threats from influenza viruses, with vaccination remaining the most cost-effective preventive measure against influenza. Mammalian cell-based influenza vaccine production has garnered significant attention due to its enhanced safety profile, process controllability, and ability to circumvent adaptive mutations commonly associated with traditional egg-based vaccines, and the particular promise of suspension cell-based production systems for their convenience, economic viability, and scalability potential. Despite years of development and an increasing number of approved animal substrate-based vaccines, numerous challenges persist, especially the incomplete understanding of influenza virus amplification features in the producing cell lines. In previous research, we developed a high-titer suspension MDCK cell-based influenza virus production process and established a high-generation MDCK cell line (MDCK-HG). This study demonstrated enhanced productive capacity of MDCK-HG cells across diverse operational conditions. The maximum hemagglutination titer achieved 15.02 Log[SUB]2[/SUB]HAU/100 μL for H9N2 strain and 12.55 Log[SUB]2[/SUB]HAU/100 μL for H1N1 strain, which evidenced by a 56.95 % and a 189.79 % increase compared to the original suspension MDCK cells. Through kinetics analyses, transcriptomic profiling, and metabolic characterization, we identified the kinetic features of high-generation cell lines for efficient influenza virus production and discovered that the redistribution of cell cycles, enhanced anti-apoptotic capabilities, elevated membrane synthesis rates, and efficient energy metabolism likely contribute to their increased viral production capacity. These findings not only deepen our understanding of the influenza vaccine production process but also provide valuable guidance for future systematic metabolic engineering efforts aimed at establishing more robust vaccine production processes.


 
Back
Top Bottom